NEW CHEWABLE SOFT TABLETS THAT ELIMINATE ECTOPARASITES FAST, EFFECTIVELY AND SAFELY.

First monthly administration fluralaner in our market

mini
2-4.5 kg
small
4.5-10 kg
medium
10-20 kg
large
20-40 kg
50 mg
FLURALANER
(mg per tablet)
100 mg
FLURALANER
(mg per tablet)
200 mg
FLURALANER
(mg per tablet)
400 mg
FLURALANER
(mg per tablet)
Download Download Download Download

For dogs weighing more than 40 kg, administer a suitable combination. The tablets are protected by a unitarily sealed aluminum blister.

* It is recommended to dose with food. Atrevia® One protects for 1 month.

Sustained action for up to 14 weeks in field tests

mini
2-4.5 kg
small
4.5-10 kg
medium
10-20 kg
large
20-40 kg
125 mg
FLURALANER
(mg per tablet)
250 mg
FLURALANER
(mg per tablet)
500 mg
FLURALANER
(mg per tablet)
1000 mg
FLURALANER
(mg per tablet)
Download Download Download Download

For dogs weighing more than 40 kg, administer a suitable combination. The tablets are protected by a unitarily sealed aluminum blister.

* It is recommended to dose with food. Atrevia® XR protects for 3 months.

CHOOSE AN IRRESISTIBLE PROTECTION: ATREVIA® ONE FOR ONE MONTH OF PROTECTION AND ATREVIA® XR FOR THREE MONTHS

CONVENIENCE

Choose the most convenient treatment for your patients. Atrevia® One for monthly protection or Atrevia® XR for 3 months of sustained protection against ectoparasites.

FAST AND EFFECTIVE

Atrevia® XR acts from the 90th minute against fleas(1), reaching 99% effectiveness at 8 hours after administration(2).

IRRESISTIBLE PROTECTION

Atrevia® has high palatability and acceptance. Acoording to fleas studies, it has a voluntary consumption of 95.65%(3).

BROAD SPECTRUM AND ENVIRONMENTAL CONTROL

Atrevia® XR is lethal against fleas, ticks, and scabies mites. Its continuous use helps to control inmature stages.

HEALTHIER SKIN

Complete recovery in cases of scabies, and the perfect complement for the treatment against flea allergy dermatitis (FAD).

SAFETY

Safe in lactating females, puppies from the 8th week and/or 2 kg of weight, dogs with MDR1 GEN mutation, and other breeds sensitive to macrocyclic lactones. No serious adverse reactions or neurological reactions have ocurred during the studies.

INNOCUITY

The systemic action of Atrevia®  allows protection without exposing families to insecticides as in topical formulations.

WATERRESISTANT

Due to its administration route, it can be used the same bath day. Its efficacy is not diminished by the contact of the pet with water.

Fleas

Atrevia® rapidly eliminates fleas within 90 minutes of administration. It is effective against Ctenocephalides felis and Ctenocephalides canis infestations. It provides environmental control, avoiding reinfestations.

Ticks

Atrevia® One has action against adult and immature form of Rhipicephalus sanguineus, Ixodes spp. and Dermacentor reticulatus and Dermacentor variabilis. Its use prevents vector-borne diseases, such as erhlichiosis, babesiosis, anaplasmosis and others.

Mites

Atrevia® One is great for the control of dermatological problems caused by Demodex canis, Sarcoptes scabiei var. canis and Otodectes cynotis. Our field studies support its effectiveness in controlling the associated clinical signs: plaques, scales, crusts, comedones, papules, pustules, alopecia and erythema.

High Palatability

Atrevia® has a high palatability and acceptance. According to field studies, it has a voluntary consumption of 98%.

Score Quantity Percentage
0 8 1.11%
1 7 0.97%
2 12 1.67%
3 693 96.25%

Protection proven by field studies under real life conditions

Atrevia® XR achieved 100% fleas elimination at 8 hours after administration, maintaining sustained efficacy for 28 days after dosing(1).

  Counting basal 90' 120' 180' 240'
Media (Median) 185(179) 0.83(1) 9.83(9.5) 30(29.5) 84(89.5)
Range of counting 95-261 0-2 2-19 19-42 38-114
Effectiveness   0.45% 5.32% 16.22% 45.41%

Average: 91' Range: 88'- 98'

Atrevia® One starts to eliminate fleas from the 90th minute after administration. The table describes the progression during the first 4 action hours the product. The baseline count is given for reference.

  Counting basal 90' 120' 180' 240'
Media (Median) 142.67(136.5) 0.67(0.5) 10.67(11.5) 25.83(25) 63.5(54.5)
Range of counting 87-238 0-2 1-21 14-43 48-101
Effectiveness   0.47% 7.48% 18.11% 44.51%

Average: 91' Range: 89'- 93'

Field tests confirm the safety of Atrevia® One and Atrevia® XR in dogs. Learn more about these studies, clic here.

LEARN MORE ABOUT OUR SUPERCHEWS™

  • Softer consistency compared to other products.

  • Exclusive blend of flavorings, which masks the taste of the active ingredients.

  • Studies support its high acceptance with a voluntary consumption of 98% in treated dogs.

  • Proprietary association of two synergistic disintegrants, facilitates disintegration of the tablets.

  • Easy administration in dogs with oral problems or reluctant to take medication.

  • Tablets in different sizes according to weight range.

LEARN MORE ABOUT OUR SUPERCHEWS™

SOFT CONSISTENCY

Softer consistency compared to other products.

ATTRACTIVE SMELL AND TASTE

Exclusive blend of flavorings, which masks the taste of the active ingredients.

HIGH ACCEPTANCE

Studies support its high acceptance with a voluntary consumption of 98% in treated dogs.

TOTAL DISINTEGRATION

Proprietary association of two synergistic disintegrants, facilitates disintegration of the tablets.

CONVENIENCE

Easy administration in dogs with oral problems or reluctant to take medication.

DIVERSITY

Tablets in different sizes according to weight range.

  1. Chávez L. 2021. Evaluación del tiempo de inicio de actividad pulguicida de una formulación oral a base de fluralaner de aplicación mensual en caninos.
  2. Chávez L., Liao V. 2021. Evaluación de la efectividad, tolerancia y residualidad de una formulación oral a base de fluralaner de aplicación mensual y una formulación oral a base de sarolaner de aplicación mensual para el tratamiento y control de pulgas en caninos naturalmente infestados.
  3. Chávez L., Liao V. 2021. Evaluación de la palatabilidad de una tableta masticable a base de fluralaner de aplicación mensual en caninos.
  4. Chávez L., Liao V. 2021.Evaluación de la seguridad de una formulación oral a base de fluralaner de aplicación mensual en caninos.
  5. Chávez L., Liao V. 2021. Evaluación de la efectividad, tolerancia y residualidad de una formulación oral a base de fluralaner de aplicación mensual y una formulación oral a base de sarolaner de aplicación mensual para el tratamiento y control de garrapatas en caninos naturalmente infestados.
  6. Chávez L., Liao V. 2021. Evaluación de la efectividad, tolerancia y residualidad de una formulación oral a base de fluralaner de aplicación mensual y una formulación oral a base de sarolaner de aplicación mensual para el tratamiento y control de ácaros y la reducción de sus signos clínicos en caninos.

Hello, vet!

If you are interested in Atrevia® One and Atrevia® XR, contact us through this form

Materials for veterinarians

In this section you can find graphic and audiovisual documents with research and field studies that support the effectiveness of Atrevia®. Learn much more about our products!

Brochure Atrevia® XR
Petmedica
Brochure Atrevia® One
Petmedica
PALATABILITY REPORT ATREVIA® XR
Author: Luis Chávez, Valeria Liao
PALATABILITY REPORT ATREVIA® ONE
Author: Luis Chávez, Valeria Liao
ACTION ONSET REPORT ATREVIA® XR
Author: Luis Alfredo Chávez Balarezo
View all materials